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ABSTRACT 
Rationale: Sufficient levels of vitamin D seem to be essential for proper immune 
function, and low levels might be associated to disease activity in Rheumatoid 
Arthritis (RA). Most studies investigate only 25OHD and not the physiologically active 
vitamin D metabolite, 1,25(OH)2D 
Objective: To investigate associations between serum level of vitamin D metabolites 
and disease activity parameters in 160 inflammatory active and treatment naïve early 
RA patients. Serum level of vitamin D metabolites (25OHD2, 25OHD3, and 
1,25(OH)2D) were measured by isotope dilution mass spectrometry and radio-
immunoassays at baseline. Disease characteristics were gender, number of tender 
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joints, number of swollen joints, DAS28-CRP, HAQ, VAS-scores, CRP, erosive 
status (Total Sharp Score; TSS), ACPA, and IgM-RF-status. Associations were 
evaluated using Spearman and Wilcoxon rank sum tests. The study was registered 
in Clinical trials; Trial registration number: NCT00209859.  
Findings: Statistically significant inverse associations were found between the active 
metabolite 1,25(OH)2D and DAS28-CRP (p=0.004, rho= -0.23), HAQ (p=0.005, rho= 
-0.22), CRP (p=0.001, rho= -0.25), VASpatient-pain (p=0.008, rho= -0.21), and a positive 
association was found to ACPA-status (p=0.04).  
Conclusion:  The vitamin D metabolite 1,25(OH)2D was inversely associated with 
disease activity and positively associated with ACPA in treatment naïve and 
inflammatory active early RA. The results indicate that in RA, both the degree of 
inflammatory activity, and the diagnostic sensitivity and specificity might affect – or 
might be affected by the level of vitamin 1,25(OH)2D. 
 
INTRODUCTION 
Besides its well-known function in calcium homeostasis, vitamin D is also a potent 
immune-modulator, meant to affect the disease activity and course of several 
autoimmune diseases, including Rheumatoid Arthritis (RA) 
 
Cells of the immunesystem contain enzymes essential for conversion of the “pre-
hormone” 25OHD to the physiologically active metabolite 1,25(OH)2D, as well as 
vitamin D receptors, responsible for the altered gene transcription and thereby 
maturation and differentiation of the immune cells. Vitamin D orchestrates the 
immune system by affecting pivotal cytokines in the delicate balance which 
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maintains immunological homeostasis.[1-3] Briefly, sufficient levels of 1,25(OH)2D 
leads to a self-accepting Th2 and Th-reg response, dominated by cytokines such as 
Interleukin(IL)4, IL5 and IL10,[4] whereas insufficient levels lead to a self-aggressive 
Th1 and Th17 response, dominated by interferon gamma, IL1, IL6 and IL17.[5]   
In the classic calcium metabolism, most vitamin D circulates as the inactive 
metabolite 25OHD, which through hepatic and renal  hydroxylation is converted to 
the physiologically active 1,25(OH)2D. Most 25OHD is bound to vitamin D Binding 
Protein (VDBP), which protects against degradation and renal elimination, thereby 
prolonging the half-life, but also sequesters 25OHD, which diminishes the bio-
availability.[6] 25OHD has a relatively long half-life on 5-6 weeks, whereas the half-
life of 1,25(OH)2D is only hours.[7] The conversion of circulating 25OHD to 
1,25(OH)2D is tightly regulated by parathyroid hormone,hypocalcaemia, 
hypophosphatemia and 1,25(OH)2D itself, thereby maintaining circulating 
1,25(OH)2D levels within the normal range (60-200 pmol/l, even in severe 25OHD 
insufficiency,[8] and the level of circulating 25OHD is therefore widely used as a 
marker of the body´s vitamin D reserves. Sufficient levels of 25OHD are above 50 
nmol/l, while lower levels are leading to compensatory secondary 
hyperparathyroidism. Levels below 25 nmol/L are considered very low, as the 
secondary hyperparathyroidism is accelerated and the bone turnover increases.[8, 9] 
Though, in some chronic inflammatory conditions, such as sarcoidosis and RA, a 
local, non-renal production of 1,25(OH)2D might contribute significantly to the 
systemic concentration.[10, 11]  
The local vitamin D metabolism in T-lymphocytes, dendritic cells, monocytes and 
macrophages is affected by cell-activation status: Antigen presenting cells constantly 
express vitamin D Receptor, whereas it is inducible in T-lymphocytes upon activation 
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[3, 12-14]. Also enzymes responsible for conversion to active 1,25(OH)2D, and 
further inactivation (1-α-hydroxylase and 24-α-hydroxylase, respectively), are 
expressed by macrophages and dendritic cells when activated.[3] The local 
enzymatic activity is in most immune cells regulated in a negative feedback 
mechanism by 1,25(OH)2D itself, thereby ensuring a balanced production of 
1,25(OH)2D. In vitro studies indicate that 1-α-hydroxylase activity is increased in e.g 
dendritic cells and macrophages during activation, probably to modulate and direct 
the ongoing immune response.[3, 15]  Concerning the 1,25(OH)2D degrading 
enzyme; 24-α-hydroxylase, the local activity is inhibited in early activation of dendritic 
cells and macrophages, whereas the inhibition decreases during maturation, 
ensuring sufficient enzymatic activity to avoid over-stimulation by 1,25(OH)2D.[3, 16] 
However, it seems that despite the local ability to convert circulating 25OHD to 
1,25(OH)2D, the availability of free 25OHD is limited by the binding to vitamin D 
binding protein, often stated as “the free hormone hypothesis”.[6, 17, 18] Thus, a 
delicate interplay between binding proteins, enzymes, receptors and activation status 
of the implicated immune-cells impacts the immunomodulatory properties of vitamin 
D. 
 
The main methods for measuring vitamin D status, assessed as Dtotal, the sum of 
25OHD2 and 25OHD3, is either immunoassays (e.g radioimmunoassays (RIA)) or 
chromatographic methods (e.g. LC-MS/MS). In general there is reliable precision 
between RIA and LC-MS/MS,[19, 20] and especially the ability to detect severe 
vitamin D deficiency is sufficient sensitive.[20] LC-MS/MS is the golden standard 
when measuring 25OHD, but RIA might be a relevant alternative method that in 
some cases reach even lower detection limits than LC-MS/MS.[21] Though; 
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detection of D2 might be lacking in immune-assay procedures, and thus the Dtotal 
might be underestimated, whereas LC-MS/MS detects 25OHD2 and 25OHD3 
separately, and therefore more precisely measures Dtotal.[20] In Denmark, food is 
only rarely fortified with vitamin D, and in such cases, as well as in vitamin D 
supplementation, vitamin 25OHD3 is used, wherefore levels of 25OHD2 is low. 
Moreover, differences in vitamin D binding protein can lead to inaccuracy;[22] and 
must be taken into account, as vitamin D binding Protein seems to be a negative 
acute phase reactant, which is lowered during systemic inflammation.[23] Awareness 
of continuous bias in evaluation method is necessary; and Berry et al[24] 
recommend to statistically harmonize values, based on a small sample of duplicate-
measurements, to ensure comparability between studies. 
Concerning detection of 1,25(OH)2D in circulation, methods are challenged by the 
very low concentrations (pmol/l) and the short half-life.[7] LC-MS/MS distinguish 
between 1,25(OH)2D derived from 25OHD2 and 25OHD3 with high sensitivity and 
specificity, whereas RIA evaluates both metabolites as one. Both methods show 
reliable sensitivity in the normal range, whereas LC-MS/MS has higher sensitivity 
than RIA when evaluating very low levels.  Generally, the correlation between RIA 
and LC-MS/MS is good when evaluating 1,25(OH)2D.[25] 
 
RA is a classic systemic, autoimmune disease that leads to joint swelling, erosions 
and disability. Patients are often affected by co-morbidities, such as osteoporosis, 
and systemic disease manifestations, mainly in the cardiopulmonal system.[26] The 
etiology of RA is not fully known, but is meant to be multifactorial, with genetic as 
well as environmental factors leading to lack of immunological self-acceptance, 
caused by an aggressive, Th1 driven immune response against the synovialis. Main 
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pro-inflammatory cytokines in RA are Tumor Necrotizing Factor, IL6 and IL17.[27] 
Owing to the immunomodulatory properties of vitamin D, associations between 
vitamin D metabolites and RA disease course is widely studied. Vitamin D levels in 
RA patients are often low, but it is not know if it is the cause or the consequence of 
the disease.[5]  In RA cell cultures, 1,25(OH)2D are shown to affect  immune-cell 
maturation and differentiation,[5] and to directly affect main pro-inflammatory 
cytokines, such as TNF, IL1, IL6,[28] as well as IL17.[29] Human studies have 
mainly focused on the commonly measured 25OHD:[30] In chronic RA patients, 
treated with Disease-Modifying Anti-Rheumatic Drugs (DMARDs), studies found 
divergent associations between 25(OH)D levels and disease activity with a tendency 
towards an inverse association, confirmed in a recent meta-analysis.[30] On the 
contrary, the physiological active 1,25(OH)2D is only rarely evaluated in vivo in RA 
cohorts, and a recent meta-analysis found studies evaluating 1,25(OH)2D in RA too 
sparse to a separate meta-analysis.[31] Though, scientific work in the field of the 
physiological active metabolite seem to increase, and a recent study indicate that the 
in vitro association to a pro-inflammatory milieu is also found in human studies.[32] 
 
The mounting evidence that vitamin D, and especially 1,25(OH)2D is involved in the 
immune-homeostasis, and that low levels of vitamin D seem to predispose to a pro-
inflammatory state, makes it relevant to evaluate associations between circulating 
levels of all vitamin D metabolites and their association to disease activity in RA 
patients with systemic inflammation. 
The aim of this study was, in inflammatory active and treatment naïve early RA 
patients, to quantify serum levels of 25OH2, 25OH3, and 1,25(OH)2D at the time of 
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diagnosis, and to test the pre-specified hypothesis that associations exist to RA 
disease-activity parameters. 
 
MATERIALS AND METHODS 
Patients: 160 patients were recruited from five Danish University Clinics from 
October 1999 to October 2002. They participated in the CIMESTRA study, eligibility 
criteria and selection of participants are described elsewhere,[33] baseline 
characteristics are listed in table 1. Patients were treatment naïve at the time of 
enrollment, and received no vitamin D or Calcium supplementation prior to inclusion. 
Vitamin D metabolites (25OHD2, 25OHD3, and 1,25(OH)2D) were evaluated at 
baseline and Dtotal calculated as the sum of 25OHD2 and 25OHD3. Number of Tender 
Joints (NTJ), Number of Swollen Joints (NSJ), Visual Analogue Scores (VAS); 
VASglobal-doctor, VASglobal-patient, VASpain-patient, C-Reactive Protein (CRP), Disease Activity 
Score in 28 joints, calculated based on CRP (DAS28-CRP), Health Assessment 
Questionnaire (HAQ), Anti-Citrullinated Protein Antibodies (ACPA), Immunoglobulin M 
Rheumafactor (IgM-RF) were evaluated at time of inclusion. 
 
Participant´s received oral and written information prior to inclusion. Written consent 
was given before enrolment. The study was in compliance with the Helsinki 
declaration, and approved by the national health authorities and local ethics 
committee (M-1959-98) and is registered at www.clinicaltrials.gov (Ref. number: 
NCT00209859). 
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Measuring vitamin D metabolites: Serum 25OHD2 and 25OHD3 were analyzed by 
isotope-dilution liquid-chromatography-mass-spectrometry (LC-MS/MS).[34] Mean 
coefficients of variation (CVs) for 25OHD3 were 8.1% at 48 nmol/l and 9.6% at 25 
nmol/l, and for 25OHD2, the CV were 8.5% at 23 nmol/l, and 8.0% at 64 nmol/l. 
1,25(OH)2D was analyzed by Radio immune assay (RIA)[35] after immune-extraction 
of the samples (1,25-dihydroxy vitamin D RIA, IDS, Boldon, UK). According to the 
supplier, the method co-determines 1,25(OH)2D2, with a cross specificity of 92% 
compared to 1,25(OH)2D3. Mean intra-assay CV of 6.8% and 9.0% were observed at 
levels of 90 and 220 pmol/l respectively.  
 
Routine laboratory assessments: IgM-RF was detected by enzyme-linked 
immunosorbent assay. ACPA IgG antibodies were determined by a second-
generation enzyme-linked immunosorbent assay (Immunoscan RA kit, Euro-
diagnostica AB, Malmo, Sweden) with the recommended 25 U/ml cut-off point. 
Serum CRP was measured using standard technique. 
 
Reporting: Reporting of the results conform to the ‘Strengthening the Reporting of 
Observational Studies in Epidemiology’ (STROBE) statement for cross-sectional 
studies. 
 
STATISTICS 
Univariate associations between the independent variable, evaluated as continuous 
vitamin D metabolite levels, and the dependent variables; NTJ, NSJ, DAS28-CRP, 
CRP, HAQ, VASpatient-pain, VASglobal-patient and VASglobal-doctor, were evaluated using 
Spearman test. Wilcoxon rank sum test evaluated associations between vitamin D 
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metabolite levels and the sub-groups IgM-RF- positive versus negative patients, 
ACPA-status positive versus negative patients, erosive status evaluated as non-
erosive disease (TSS = 0) or erosive disease (TSS > 0), and season of diagnosis, 
dichotomized as summer or winter (winter defined as diagnosis established from 
November to April). Significance was defined as the 5 % level. The “R” software 
package was used, and analyses were performed by an independent statistician.  
 
RESULTS   
69 patients (42%) had low Dtotal, (below 50 nmol/l). 15 patients (10 %) had very low 
levels below 25 nmol/l. 16 patients (10 %) had low 1,25(OH)2D levels, (below 60 
pmol/l). The majority of these (75 %) had concomitantly low Dtotal. 
 
Statistically significant inverse associations were found between 1,25(OH)2D 
(median 95 pmol/l, range 33–268), and RA disease variables as DAS28-CRP (rho=-
0.23, p=0.004), HAQ (rho=-0.22, p=0.005), CRP (rho=-0.25, p=0.001), and VASpatient-
pain (rho=-0.21, p=0.008).There were no significant associations to NSJ (rho=-0.09, 
p=0.24), NTJ (rho=-0.09, p=0.26), VASglobal-patient (rho=-0.14, p=0.08) or VASglobal-doctor 
(rho=-0.14, p=0.09). Significant positive association was found between 1,25(OH)2D 
and ACPA-status (p=0.04);  but not to IgM-RF status (p=0.35), nor to erosive or non-
erosive status at baseline (p=0.29). Please see figure 1. 
 
Median 25OHD2 was 0 nmol/l (range 0–37). This was significantly inversely 
associated with NTJ (rho=-0.17, p=0.03) and not to other variables, see figure 1 and 
table 2. 
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Median 25OHD3 was 52 nmol/l (range 0–145), this was not associated to any 
variables, see table 2. 
 
Seasonal variation was found for 25OHD3, with significantly lower levels in patients 
diagnosed during the winter (p=0.003). No significant seasonal variation in levels of 
25OHD2 (p=0.46) and 1,25(OH)2D (p=0.15) was found. 
 
For all results, see table 2. 
 
Concerning missing data, 3 patients had missing values of vitamin D metabolite 
levels at baseline, and 3 patients had missing values of CRP and therefore of 
DAS28. There are no indications that these data were not missing at random, and 
therefore these patients were not excluded during the analyses. 
 
DISCUSSION  
This study is one of few human studies investigating all vitamin D metabolites. Main 
finding is, in 160 early diagnosed, treatment-naive RA patients that low serum levels 
of 1,25(OH)2D are associated to several parameters for RA disease activity, 
including CRP, HAQ, VASpatient-pain and DAS28-CRP. Despite 90 % of the cohort had 
1,25(OH)2D in the normal range, there were several strong associations to markers 
for disease activity when evaluating the metabolite as a continuous variable. This 
was chosen prior to analyses, to investigate if levels lower in the normal range was 
associated to markers of disease activity. We find this approach to be relevant 
because of the gap in knowledge concerning  cut-offs in vitamin D metabolites and 
proper immune-function. Even though 1,25(OH)2D is closely regulated under normal 
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physiological conditions,[3] our results indicate that the regulation might be disturbed 
during systemic inflammation.  
Activation status and cytokine production of T-lymphocytes and antigen presenting 
cells affect the local vitamin D metabolism, leading to increased local 1,25(OH)2D 
synthesis.[3, 12-14, 36] It is somewhat contra-intuitive to our results, where lower 
levels of 1,25(OH)2D are associated to elevated markers of disease activity, 
including markers of systemic inflammation, such as CRP and DAS28CRP, and 
denotes that much is still unknown concerning vitamin D and inflammation in RA- as 
well as in non-RA subjects.  
Our study adds to the literature that 25OHD, a commonly used marker for the body`s 
vitamin D reserve, is not associated to RA-disease activity or diagnostic criteria in 
early, treatment-naive RA patients. Further, the tradition of only measuring 25OHD 
when assessing vitamin D status in RA patients, is challenged by our results. 
 As expected, 25OHD levels showed seasonal variation, owing to increased 
cutaneous production during sun exposure in the summer.[37] This is a factor that 
must be taken into consideration, whenever studying associations to 25OHD. In 
small studies, this weakens the power, whereas our finding of no seasonal variation 
in 1,25(OH)2D in newly diagnosed RA patients might be useful knowledge when 
assessing vitamin D in future studies. 
 
Associations between 1,25(OH)2D and disease activity in early RA is rarely 
assessed in human studies. Our finding of a negative association between 
1,25(OH)2D and DAS28 is in agreement with the findings of Liu et al [32] in 208 
treatment naïve RA patients. In 206 early, inflammatory poly-arthritis patients treated 
with DMARD up to 6 weeks, Patel et al finds significant inverse associations 
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between baseline 25OHD and NTJ, CRP, HAQ and DAS28-CRP, whereas the only 
association regarding 1,25(OH)2D was for the HAQ-score.[38] Differences in study 
populations, treatment and statistical methods are possible explanations for the 
discrepancies when compared to our results: Liu et al evaluates patients fulfilling 
ACR1987 classification criteria with a mean disease duration of 9 years, Patel et al 
evaluates undifferentiated poly-arthritis patients with a mean disease-duration of 4 
months, whereas symptom-duration in the CIMESTRA cohort was 3.2 months and 
all patients full-filled the ACR1987 classification criteria.[33] Liu et al evaluates 
DMARD- and steroid naïve patients like the CIMESTRA cohort, whereas Patel et al 
accept DMARD treatment 6 weeks prior to inclusion.  Moreover, Liu et al evaluates 
vitamin D as dichotomized variable, whereas Patel et al evaluates changes in 
disease activity markers per 10 unit change in vitamin D metabolites. 
 
Our finding of an inverse association between 1,25(OH)2D and CRP has also been 
observed in healthy subjects.[39] A possible explanation is interaction between 
vitamin D, calcium-homeostasis and IL-6, affecting the production of acute-phase 
reactants.[40] 
 
The association of 1,25(OH)2D to CRP and ACPA, and of 25OH2D to NTJ add credit 
to the notion that the level of vitamin D metabolites may influence on diagnostic 
specificity and sensitivity associated with the ACR/EULAR2010 classification criteria 
for  RA.[26] Though, other studies evaluating vitamin D and ACPA departs from our 
results: Liu et al[32] found a negative association between ACPA and 25OHD, and 
similarly, Kerr et al found association between low levels of 25OHD and ACPA-
positivity in multivariate analyses.[41] On the contrary, Feser et al found no 
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association between 25OHD and ACPA in subjects susceptible to RA.[42] To our 
knowledge, no previous studies have evaluated associations between ACPA and the 
active vitamin D metabolite 1,25(OH)2D. The first step in the citrullination process is 
calcium-dependent, and 1,25(OH)2D is essential in maintaining calcium 
homeostasis, so it can be hypothesized that the association might be linked to the 
calcium-homeostasis. However, the association between 1,25(OH)2D and ACPA 
needs further investigation before conclusions can be reached.  
 
 
We found no significant associations between any of the vitamin D metabolites and 
presence of erosions at the time of RA diagnosis. Human RA studies evaluating 
associations between vitamin D metabolites and erosions have only evaluated 
25OHD and not the active metabolite, and found no associations.[43, 44] Receptors 
responsible for the action of vitamin D are present in the RA synovialis, and cell 
culture studies have shown that 1,25(OH)2D can affect chondrolysis,[17] and that low 
levels of 1,25(OH)2D might increase the risk of bone erosions.[45] This is not 
confirmed in human studies. In our human RA study, the serum level of vitamin D 
metabolites were not associated with the TSS, thereby supporting that no 
association exists between vitamin D metabolites and RA erosions.  
 
This study has some limitations. The cross-sectional design does not investigate 
causality, and it can be argued that the associations of low vitamin D metabolite 
levels to RA disease activity are the consequence rather than the cause of the 
disease. Moreover, vitamin D status is the result of a delicate interplay with both 
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immune-cells and calcium-homeostasis, and a limitation in our study is the lack of 
measuring calcium, phosphate, parathyroid hormone and albumin. 
Furthermore, a common challenge in vitamin D studies is the vitamin D 
measurement method, as great variability between methods exists, thereby affecting 
the between-studies comparability.[19, 20] In this study, 25OHD2 and 25OHD3 were 
measured using LS-MS/MS, which detects D2 and D3 separately, whereas 
1,25(OH)2D was measured with RIA, which detects both D2 and D3-derived 
1,25(OH)2D.[35] We find the variation coefficients provided by the suppliers 
acceptably low across the low and normal range.[34, 35] 
 
Possible confounders are adiposity, physical capacity, age and renal disease, which 
all are associated to both vitamin D deficiency and RA disease activity. The lipophilic 
vitamin D clusters in adipose tissue, and leads to lower levels of circulating vitamin 
D, and adipose tissue is known to contribute to inflammation in RA.[46] Physical 
inactivity is common in RA, and is associated with inflammatory activity, pain and 
fatigue,[47] whereas some studies also associate physical inactivity to lower vitamin 
D levels, including 1,25(OH)2D.[48] Low vitamin D levels are common in the 
elderly,[8] and in patients with renal insufficiency. The exclusion of patients over 75 
years of age and patients with renal insufficiency could lead to underestimation of 
the prevalence of vitamin D deficiency in our cohort, compared to the general 
population, thereby weakening the external validity. 
 
The strengths of our study are the well characterized, early and treatment-naïve RA 
patients and the measurement of both 25OHD and 1,25(OH)2D serum levels. 
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The novelty of this study is the evaluation of all vitamin D metabolites, compared to 
the vast amount of reports in 25OHD only. We find it relevant to investigate this gap 
in knowledge, as the 1,25(OH)2D is the physiologically active metabolite, which is 
responsible for the immunological actions of vitamin D, as well as in the calcium 
homeostasis. That said, knowledge concerning calcium homeostasis suggests that 
sufficient levels of circulating Dtotal is necessary for local conversion to 
1,25(OH)2D.[5, 18] Off note, our results show that most patients have 1,25(OH)2D in 
the normal range, even when circulating Dtotal is extremely low. This finding is 
expected, as the circulating levels of 1,25(OH)2D is strictly regulated by calcium, 
parathyroid hormone and 1,25(OH)2D itself, as part of the calcium homeostasis, 
even in severe vitamin D deficiency. We find that the evaluation of 1,25(OH)2D as a 
continuous variable shows a clear trend toward an inverse association to several RA 
disease activity parameters. However, the study design does not allow conclusions 
concerning causality, and the question; does low levels of vitamin D; especially 
1,25(OH)2D, lead to increased RA disease activity, or does the systemic 
inflammation lead to lower levels of circulating 1,25(OH)2D, is still open. Preferably, 
this should be evaluated in large, prospective cohorts. 
 
In summary, our study revealed biological plausible associations between circulating 
1,25(OH)2D and several parameters relevant for diagnosis and assessment of 
disease activity in a cohort of inflammatory active and treatment-naïve early RA 
patients. These results are likely applicable in early RA patients of Scandinavian 
ancestry. In future studies we recommend measurement of all vitamin D metabolites 
as well as calcium, phosphate, parathyroid hormone, and albumin, to evaluate the 
interplay between vitamin D metabolites and calcium metabolism in RA. 
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Table 1: Baseline demographic, clinical and immunological characteristics of 160 early 
RA patients who were inflammatory active and treatment naïve. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Baseline 
n = 160 
Age (years)   53.0 (20.4–75.2) 
Female sex (%) 67 
Disease duration (weeks)  14.1 (6.1–26.6) 
IgM-RF positive baseline (%)  66 
ACPA positive baseline (%)  58 
NTJ (0-40)  14 (0–39) 
NSJ (0-40)  11 (2–37) 
VASglobal-doctor (0-100 mm)   58 (3–98) 
VASpatient-pain (0-100 mm)  46 (2–100) 
VASglobal-Patient (0-100 mm)  50 (3–100) 
CRP (mg/l)  20.1 (0.0–253.1) 
DAS28-CRP  5.5 (2.23–8.38) 
HAQ (0–3)  0.937 (0–2.875) 
1,25(OH)2D (pmol/l) 95 (33–268) 
1,25(OH)2D below 60 pmol/l (%) 9,3 
25OHD3 (nmol/l) 52 (0-145) 
Dtotal (nmol/l) 53 (0–145) 
Dtotal below 50 nmol/l (%) 43.1 
Erosive disease (TSS> 0) (%) 61 
 
Values are median, unless otherwise stated. Values in parentheses are range. 
Abbreviations:  IgM-RF: Immunoglobulin M Rheuma factor, ACPA: Anti Citrullinated Protein 
Antibodies, NTJ: Number of Tender Joints. NSJ: Number of Swollen joints. VAS: Visual 
Analogue Scores. CRP: C-reactive Protein. DAS28-CRP: Disease Activity Score calculated in 
28 joint counts, based on CRP. HAQ: Health Assessment Questionnaire.Dtotal: The sum of 
25OHD2 and 25OHD3 TSS: Total Sharp Score 
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Table 2: Baseline D vitamin levels and associations with RA disease activity 
parameters and immunological status in 160 early RA patients who are inflammatory 
active and treatment naïve. 
 
 1,25(OH)2D  25OHD2  25OHD3 
 rho p  rho p  rho p 
NTJ -0.09 0.26  -0.17 0.03  -0.04 0.59 
NSJ -0.09 0.24  -0.06 0.48  -0.07 0.40 
VASdoctor  -0.14 0.09  0.03 0.74  -0.13 0.10 
VASglobal -0.14 0.08  -0.04 0.59  0.02 0.79 
VASpatient -0.21 0.01  -0.03 0.67  -0.04 0.61 
CRP  -0.25 0.001  0.03 0.74  -0.15 0.06 
DAS28-CRP  -0.23 0.004  -0.05 0.54  -0.06 0.44 
HAQ   -0.22 0.010  -0.004 0.96  -0.04 0.62 
ACPA-status  0.04   0.52   0.38 
IgM-RF-status  0.35   0.96   0.96 
Baseline TSS  0.29   0.73   0.32 
Season of diagnosis  0.148   0.463   0.003 
Spearman test was used for univariate associations of D vitamin metabolite levels to NTJ, NSJ, VASglobal-doctor, VASglobal-patient, 
VASpatient-pain, CRP, DAS28-CRP and HAQ. P-value and regression coefficient presented. 
Wilcoxon rank sum test was used to evaluate ACPA-status, IgM-RF-status, baseline erosive status,and season of diagnosis.  
Significant p values in bold 
Abbreviations: NTJ: Number of Tender Joints. NSJ: Number of Swollen joints. VAS: Visual Analogue Scores. CRP: C-reactive 
Protein. DAS28-CRP: Disease Activity Score calculated in 28 joint counts, based on CRP. HAQ: Health Assessment Questionnaire. 
ACPA: Anti Citrullinated Protein Antibodies. IgM-RF: Immunoglobulin M Rheuma factor.TSS: Total Sharp Score Dtotal: The sum of 
25OHD2 and 25OHD3 
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